Receive our newsletter – data, insights and analysis delivered to you
  1. News
April 24, 2020

Gilead says leaked Covid-19 trial data of remdesivir inconclusive

Gilead's remdesivir has failed to show benefit in a clinical trial conducted to treat Covid-19 patients in China, according to data that the World Health Organization (WHO) accidentally posted on its website.

Gilead’s remdesivir has failed to show benefit in a clinical trial conducted to treat Covid-19 patients in China, according to data that the World Health Organization (WHO) accidentally posted on its website.

In response to the leaked results, which have now been taken down by the WHO, Gilead said that the trial was stopped early and hence the findings are inconclusive.

According to the data, intravenous infusion of the drug did not improve patients’ condition or decrease the virus’ presence in the bloodstream, noted Reuters citing the draft documents published by the WHO.

The rate of death was similar in both the groups, with 13.9% in remdesivir arm compared to 12.8% in the placebo arm.

News website STAT captured a screenshot of the publication, which showed that 237 patients have been enrolled in the trial. Of the total participants, 158 were treated with remdesivir while 79 were on a placebo.

Commenting on the publication, WHO said that the draft is still under peer review and is yet to be officially released.

Content from our partners
Africa’s last mile: Building viable vaccine supply chains
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Patient-centric pharma logistics: How CRYOPDP delivers hope worldwide

In a statement, Gilead noted that the WHO posting included inappropriate characterisations of the study, which was stopped early due to low enrollment and cannot be used for ‘statistically meaningful conclusions’.

The company added: “As such, the study results are inconclusive, though trends in the data suggest a potential benefit for remdesivir, particularly among patients treated early in disease.

“We understand the available data have been submitted for peer-reviewed publication, which will provide more detailed information from this study in the near future.”

Currently, several Phase III studies are being conducted to assess remdesivir as a Covid-19 treatment.

Gilead expects to report results from its open-label study in patients with severe disease by the end of this month, and from the study for moderate disease by the end of next month.

Related Companies

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU